Neuramedy - Crunchbase Company Profile & Funding

Q: Who invested in Neuramedy?

Neuramedy has 5 investors including STIC Ventures And Industrial Bank of Korea.

Q: When was the last funding round for Neuramedy?

Neuramedy closed its last funding round on obfuscated from a Series A round.

Q: How much funding has Neuramedy raised to date?

Neuramedy has raised obfuscated.

Overview

Neuramedy

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Neuramedy

CB Rank

130477

Neuramedy provides research on neurodegenerative disorders focused on alpha-synuclein and related mechanisms for Parkinson's disease.

Founded

obfuscation

Private

Series A

Songdong, Seoul-t'ukpyolsi, South Korea

11-50

www.neuramedy.com

Biotechnology

Market Research

Medical

Professional Services

Funding Rounds

Series A

OBF

obfuscation

Pre-Seed

OBF

obfuscation

Details

Legal Name

Neuramedy Co.,Ltd

Operating Status

Active

Company Type

For Profit

About the Company

Neuramedy develops medical supplies and lifescience.

Phone Number

+82 2 765 3344

Contact Email

contact@neuramedy.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

Tomaralimab

An antibody targeting TLR2 to prevent the propagation of alpha-synuclein and reduce neuroinflammation in Parkinson's disease.

NM-101

A small molecule aimed at inhibiting the abnormal aggregation of alpha-synuclein and promoting the clearance of aggregates.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Neuramedy	3	obfuscated obfuscation	—	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
STIC Ventures	—	Series A - Neuramedy	—
STIC Ventures	—	Series A - Neuramedy	—
STIC Ventures	—	Series A - Neuramedy	—
STIC Ventures	—	Series A - Neuramedy	—
STIC Ventures	—	Series A - Neuramedy	—